Company Information

  

Address: 245 FIRST STREET
SUITE 1100 
City: CAMBRIDGE 
State: MA 
Zip Code: 02142 
Telephone: 617-871-2098 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on developing and delivering novel therapeutics for patients based on hypoxia-inducible factor, or HIF, biology, and building our pipeline while leveraging our development and commercial expertise in renal disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions. Pharmacologic modulation of the HIF pathway may have broad therapeutic applications. Our lead product candidate, vadadustat, is an oral therapy in Phase 3 development, which has the potential to set a new standard of care in the treatment of anemia associated with chronic kidney disease (CKD). Our management team has extensive experience in developing and commercializing drugs for the treatment of renal and metabolic disorders, as well as a deep understanding of HIF biology.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-3.61NAN/E
03/2017-4.05NAN/E
12/2016-3.60NAN/E
09/2016-3.28NAN/E
06/2016-3.02NAN/E
03/2016-2.46NAN/E
12/2015-2.29NAN/E
09/2015-1.50NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.37Total Liab/Total Assets0.77
Net Inc/Total Assets-0.45Total Liab/Inv Cap1.25
Net Inc/Inv Cap-0.73Total Liab/Comm Equity0.64
Pretax Inc/Net Sales-88.43Interest Coverage RatioNA
Net Inc/Net Sales-88.43Curr Debt/EquityNA
Cash Flow/Net Sales37.72LTD/EquityNA
SG&A/NetSales14.47Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover0.09Quick Ratio2.59
Inventory TurnoverNACurrent Ratio2.59
Inventory Day SalesNANet Rec/Curr Assets0.11
Net Sales/Work Cap0.01Inv/Curr AssetsNA
Net Sales/PP&E0.59  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 28.52 20.87 1.54 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 6.91 5.79 6.14 4.94
Operating Income -22.14 -44.97 -38.04 -36.18
Interest Exp NA NA NA NA
Pretax Income -21.52 -44.54 -37.86 -36.31
Other Income 0.62 0.43 0.18 -0.13
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -21.52 -44.54 -37.86 -36.31

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 321.22 251.81 260.34 161.32
Receivables - Total 0.00 0.00 33.82 NA
Inventories - Total NA NA NA NA
Total Current Assets 332.39 255.05 296.32 165.15
Net Property, Plant & Equipment 2.93 2.90 2.61 2.69
Total Assets 336.82 259.26 300.22 169.12
Liabilities        
Accounts Payable 39.06 49.36 32.30 26.14
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 181.59 133.46 114.27 26.14
Long-Term Debt NA NA NA NA
Total Liabilities 279.82 228.64 232.10 68.41
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -363.20 -341.68 -297.14 -259.27
Treasury Stock NA NA 0.00 0.00
Total Stockholders' Equity 57.00 30.62 68.12 100.71
Total Liabilities and Stockholders' Equity 336.82 259.26 300.22 169.12

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities 24.36 -9.53 95.67 -28.24
Net Cash Provided by Investing Activities -31.69 -92.30 22.31 45.57
Net Cash Provided by Financing Activities 45.47 1.75 3.53 2.33

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-8.20--
12/20130.00-13.17--
12/20140.00-37.03-8.04
12/20150.00-60.72-2.29
12/20161.54-135.75-3.60
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1713027,57858.49




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.